Novavax
company in Gaithersburg, Maryland
NVAX Nasdaq
ISIN US6700024010 SEC CIK 1000694 LEI 529900J4GJHPEPQ23205
Follow Novavax
Weekly email: filings, results
Revenue, last quarter
$68.3M
−3% vs same quarter last year
Net income
−$31.4M
+84.5% vs same quarter last year
EPS, diluted
−$0.19
+84.8% vs same quarter last year
Operating cash flow
−$94.2M
−187.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.1B | $440.3M |
| FY24 | $682.2M | −$187.5M |
| FY23 | $983.7M | −$545.1M |
| FY22 | $2B | −$657.9M |
| FY21 | $1.1B | −$1.7B |
| FY20 | $475.6M | −$418.3M |
| FY19 | $18.7M | −$132.7M |
| FY18 | $34.3M | −$184.7M |
| FY17 | $31.2M | −$183.8M |
| FY16 | $15.4M | −$280M |
| FY15 | $36.3M | −$156.9M |
| FY14 | $30.7M | −$82.9M |
| FY13 | $20.9M | −$52M |
| FY12 | $22.1M | −$28.5M |
| FY11 | $14.7M | −$19.4M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 93.5% | 40.3% | 39.2% |
| FY24 | 70.3% | −36.5% | −27.5% |
| FY23 | 65.1% | −57.6% | −55.4% |
| FY22 | 54.5% | −32.5% | −33.2% |
| FY21 | 100% | −147.1% | −152.1% |
| FY20 | 100% | −87.6% | −87.9% |
| FY19 | - | −646.1% | −711% |
| FY18 | - | −507.2% | −538.8% |
| FY17 | - | −550.8% | −589.5% |
| FY16 | - | −1752.8% | −1823.5% |
| FY15 | - | −433.8% | −432.9% |
| FY14 | - | −273% | −270.5% |
| FY13 | - | −250.7% | −248.5% |
| FY12 | - | −134.4% | −129.1% |
| FY11 | - | −146.9% | −131.8% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | $265.5M |
| FY20 | −$97.2M |
| FY19 | −$138.5M |
| FY18 | −$186.2M |
| FY17 | −$148.7M |
| FY16 | −$277M |
| FY15 | −$144.4M |
| FY14 | −$74.3M |
| FY13 | −$51.1M |
| FY12 | −$22.6M |
| FY11 | −$24.2M |
- Novavax
- Healthcare median
Show the numbers
| Year | Novavax | Healthcare median |
|---|---|---|
| FY25 | 39.2% | −30.6% |
| FY24 | −27.5% | −47% |
| FY23 | −55.4% | −58% |
| FY22 | −33.2% | −80.4% |
| FY21 | −152.1% | −71.9% |
| FY20 | −87.9% | −62.2% |
| FY19 | −711% | −46.3% |
| FY18 | −538.8% | −49.6% |
| FY17 | −589.5% | −45.9% |
| FY16 | −1823.5% | −36% |
| FY15 | −432.9% | −38.4% |
| FY14 | −270.5% | −35.5% |
| FY13 | −248.5% | −37.1% |
| FY12 | −129.1% | −29.1% |
| FY11 | −131.8% | −27.9% |